"I, P(NR9087)" . "7"^^ . "Fiala, Ond\u0159ej" . . "F\u00EDnek, Jind\u0159ich" . "Bortl\u00ED\u010Dek, Zbyn\u011Bk" . "Min\u00E1rik, Marek" . . . "Anticancer Research" . "4"^^ . . "Topol\u010Dan, Ond\u0159ej" . "Background: Tumor biomarkers are used for predicting therapy effect and prognosis of patients with non-small cell lung cancer (NSCLC). We focused on their potential role in prediction of the efficacy of erlotinib. Patients and Methods: In a total of 144 patients with advanced-stage (IIIB or IV) NSCLC treated with erlotinib, pre-treatment levels of soluble carcinoembryonic antigen (CEA) and cytokeratin markers in serum were measured. Results: The median progression-free and overall survival for patients with a high level of carcinoembryonic antigen (CEA) was 1.9 and 8.6 vs. 2.9 and 16.1 months for patients with low CEA (p=0.046 and p=0.116). The respective medians for patients with a high level of cytokeratin-19 fragment were 1.9 and 6.1 vs. 3.4 and 23.8 months for patients with the low cytokeratin-19 fragment (p<0.001 and p<0.001). Conclusion: High pre-treatment serum levels of one or both biomarkers are associated with poor outcome of patients with NSCLC treated with erlotinib."@en . . "000336875200067" . . "RIV/00216208:11140/14:10271887!RIV15-MSM-11140___" . "Background: Tumor biomarkers are used for predicting therapy effect and prognosis of patients with non-small cell lung cancer (NSCLC). We focused on their potential role in prediction of the efficacy of erlotinib. Patients and Methods: In a total of 144 patients with advanced-stage (IIIB or IV) NSCLC treated with erlotinib, pre-treatment levels of soluble carcinoembryonic antigen (CEA) and cytokeratin markers in serum were measured. Results: The median progression-free and overall survival for patients with a high level of carcinoembryonic antigen (CEA) was 1.9 and 8.6 vs. 2.9 and 16.1 months for patients with low CEA (p=0.046 and p=0.116). The respective medians for patients with a high level of cytokeratin-19 fragment were 1.9 and 6.1 vs. 3.4 and 23.8 months for patients with the low cytokeratin-19 fragment (p<0.001 and p<0.001). Conclusion: High pre-treatment serum levels of one or both biomarkers are associated with poor outcome of patients with NSCLC treated with erlotinib." . "Bene\u0161ov\u00E1, Lucie" . . . . "Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib" . . . . "11140" . "38780" . "RIV/00216208:11140/14:10271887" . "6"^^ . . . . "Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib"@en . . . . . "GR - \u0158eck\u00E1 republika" . "Pe\u0161ek, Milo\u0161" . "prediction; EGFR-TKI; NSCLC; erlotinib; CYFRA 21-1; CEA; Tumor marker"@en . . "Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib"@en . . "34" . "[0B49BC406E31]" . "6" . "0250-7005" . . . "Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib" .